Kwmg LLC makes new investment in AbbVie Inc. (NYSE: ABBV)

Kwmg LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,268 shares of the company’s stock, valued at approximately $205,000.

→ “Prepare for five years of famine” (From Legacy Research)

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. First Community Trust NA boosted its stake in shares of AbbVie by 2.3% in the fourth quarter. First Community Trust NA now owns 12,791 shares of the company’s stock valued at $2,067,000 after acquiring an additional 289 shares in the last quarter. Avitas Wealth Management LLC boosted its stake in shares of AbbVie by 25.1% in the fourth quarter. Avitas Wealth Management LLC now owns 34,626 shares of the company’s stock valued at $5,596,000 after acquiring an additional 6,945 shares in the last quarter. CHURCHILL MANAGEMENT Corp raised its stake in shares of AbbVie by 2.4% during the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 79,826 shares of the company’s stock valued at $12,901,000 after acquiring an additional 1,876 shares in the last quarter. McGuire Investment Group LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $231,000. Finally, Gries Financial LLC boosted its stake in shares of AbbVie by 5.2% in the fourth quarter. Gries Financial LLC now owns 17,610 shares of the company’s stock valued at $2,846,000 after acquiring an additional 866 shares in the last quarter. Institutional investors own 67.71% of the company’s shares.

Wall Street analysts forecast growth

ABBV is the subject of a number of analyst reports. SVB Leerink upgraded shares of AbbVie from an “underperform” rating to a “market perform” rating and lifted their target price for the company from $135.00 to $153.00 in a research note on Friday, February 10th. Piper Sandler boosted their target price on shares of AbbVie from $157.00 to $163.00 and gave the company an “overweight” rating in a research note on Thursday, February 9th. Morgan Stanley cut their target price on shares of AbbVie from $182.00 to $178.00 and set an “overweight” rating for the company in a research note on Friday, February 10th. Piper Jaffray Companies boosted their price objective on shares of AbbVie from $157.00 to $163.00 and gave the stock an “overweight” rating in a research report on Friday, February 10th. Finally, StockNews.com lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 10th. Nine research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. AbbVie presently has an average rating of “Hold” and an average price target of $161.12, according to MarketBeat.

Internal activity

In other news, Director Roxanne S. Austin sold 10,000 shares of the business’s stock in a transaction on Friday, February 17th. The shares were sold at an average price of $150.50 for a total value of $1,505,000.00. Following the completion of the transaction, the director now owns 40,705 shares of the company’s stock, valued at approximately $6,126,102.50. The sale was disclosed in a filing with the Securities and Exchange Commission, which is available at this link. In related news, EVP Azita Saleki-Gerhardt sold 25,000 shares of the business’s stock in a transaction on Friday, February 17th. The shares were sold at an average price of $149.53, for a total value of $3,738,250.00. Following the sale, the executive vice president now directly owns 233,208 shares of the company’s stock, valued at approximately $34,871,592.24. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this hyperlink. Also, Director Roxanne S. Austin sold 10,000 shares of the business’s stock in a transaction on Friday, February 17th. The shares were sold at an average price of $150.50, for a total transaction of $1,505,000.00. Following the completion of the sale, the director now directly owns 40,705 shares in the company, valued at $6,126,102.50. Disclosure of this sale can be found here. Insiders sold 159,746 shares of company stock valued at $24,267,450 in the last quarter. Company insiders own 0.08% of the company’s shares.

AbbVie’s pricing performance

ABBV opened at $154.22 on Friday. The company has a fifty day moving average of $151.13 and a two hundred day moving average of $150.93. The company has a debt-to-equity ratio of 3.42, a quick earnings ratio of 0.84 and a current ratio of 0.96. AbbVie Inc. has a 52-week low of $134.09 and a 52-week high of $175.91. The firm has a market cap of $272.88 billion, a PE ratio of 23.33, a P/E/G ratio of 3.50 and a beta of 0.62.

AbbVie (NYSE: ABBV – Get Rating ) last posted its earnings results on Thursday, February 9th. The company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $3.54 by $0.06. AbbVie had a net margin of 20.39% and a return on equity of 154.52%. The firm had revenue of $15.12 billion during the quarter, compared to analysts’ estimates of $15.30 billion. In the same quarter last year, the business earned $3.31 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, analysts expect AbbVie Inc. to post 11 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Stockholders of record on Friday, April 14th will be paid a $1.48 dividend. This represents a $5.92 annual dividend and a dividend yield of 3.84%. The ex-dividend date is Thursday, April 13th. AbbVie’s dividend payout ratio (DPR) is 89.56%.

About AbbVie

(Get Rating)

AbbVie, Inc. is a research-based biopharmaceutical company engaged in the development and sale of pharmaceutical products. It focuses on the treatment of conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology, oncology including blood cancer, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological diseases such as Parkinson’s, metabolic , including thyroid disease and complications related to cystic fibrosis, endometriosis-related pain, and other serious health conditions.

Read more

Want to see what other hedge funds hold ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for AbbVie Inc. (NYSE: ABBV – Get Rating ).

This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider AbbVie, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes a nosedive … and AbbVie wasn’t on the list.

Although AbbVie currently has a “Hold” rating among analysts, the top-rated analysts think these five stocks are better buys.

Check out the five stocks here